EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Testosterone in Relapsing–Remitting Multiple Sclerosis: A Case–Control Study

Iwona Rościszewska-Żukowska iD, Małgorzata Popiel, Adam Perenc iD, Julia Rudnicka-Czerwiec, Ilona Malska, Halina Bartosik-Psujek iD

Journal of Clinical Medicine · 06.06.2026 · 15 (12) · 4401

DOI: 10.3390/jcm15124401 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 06.06.2026. Verfasst von Iwona Rościszewska-Żukowska und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, St. Jadwiga Queen Clinical Hospital, 60 Lwowska Street, 35-301 Rzeszow, Poland. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: This study aimed to evaluate the prevalence of hypogonadism in men with RRMS (relapsing–remitting multiple sclerosis) who are undergoing treatment with disease-modifying therapies (DMTs) and its association with clinical and magnetic resonance imaging (MRI) parameters.

Methods

A total of 126 male patients with RRMS, aged 18–67 years, receiving DMTs and a group of 35 age- and BMI-matched healthy individuals were enrolled. Clinical and demographic data were collected, including neurological disability (EDSS, T25FW, 9-HTP, SDMT), and MRI findings. Symptoms of androgen deficiency and depression were assessed using ADAM questionnaire and Beck Depression Inventory, while quality of life was evaluated using MSIS-29. Serum total testosterone (TT), sex hormone-binding globulin (SHBG), and free testosterone (fT) were measured in two stored morning blood samples.

Results

A total of 118 (93.6%) MS patients (median age of 38.8 y) had normal TT levels; only 2 (1.6%) MS patients and 2 (5.7%) healthy controls had below-normal levels. Meanwhile, low fT levels were observed in 53 (43.7%) MS patients and 12 (34.3%) controls. However, the fT level was significantly lower in the MS patients under 38 years of age than in control individuals (p = 0.015). Only depression from all concomitant diseases was more prevalent in MS patients with low fT (p = 0.016). There was no correlation between low fT and clinical (EDSS, T25FT, SDMT) and MRI (new T2 and new Gd+ lesions) parameters but a longer disease duration and a higher total number of steroid treatments were associated with below-normal fT levels (p = 0.048 and p = 0.003, respectively). Change of DMT and current and previous DMT type did not correlate with low fT. Patients with low fT levels had a higher median score on the BDI (8.00; IQR: 3.00–12.50 vs. 5.00; IQR: 1.00–10.50) (p = 0.034) and the higher median ADAM questionnaire score (4.00 [IQR: 2.00–7.50] vs. 2.00 [IQR: 0.00–6.00]) (p = 0.034). Only a longer duration of MS (11.83 years) exhibited a significant positive correlation with the risk of a low fT level (OR = 1.19, CI 95%: 1.06–1.35, p = 0.004) in multivariate logistic analysis.

Conclusions

Total testosterone level was normal in most male RRMS patients; however, low free testosterone level was observed, in particular in younger MS patients. Depression was more prevalent in patients with low fT but longer duration was a significant risk factor for a low fT level.

Schlagwörter

Stichwörter der Autor:innen

free testosteronehypogonadismmultiple sclerosis

Autor:innen und Institutionen

  • Department of Neurology, St. Jadwiga Queen Clinical Hospital, 60 Lwowska Street, 35-301 Rzeszow, Poland.
  • Department of Neurology, Collegium Medicum, University of Rzeszow, 16C Rejtana Street, 35-959 Rzeszow, Poland.

ORCID-Profile: Iwona Rościszewska-Żukowska, Adam Perenc, Halina Bartosik-Psujek

Zitieren

APA

Rościszewska-Żukowska, I., Popiel, M., Perenc, A., Rudnicka-Czerwiec, J., Malska, I., & Bartosik-Psujek, H. (2026). Testosterone in Relapsing–Remitting Multiple Sclerosis: A Case–Control Study. Journal of Clinical Medicine, 15(12), 4401. https://doi.org/10.3390/jcm15124401

Vancouver

Rościszewska-Żukowska I, Popiel M, Perenc A, Rudnicka-Czerwiec J, Malska I, Bartosik-Psujek H. Testosterone in Relapsing–Remitting Multiple Sclerosis: A Case–Control Study. Journal of Clinical Medicine. 2026;15(12):4401. doi:10.3390/jcm15124401

BibTeX
@article{Rociszewskaukowska2026,
  author = {Rościszewska-Żukowska, Iwona and Popiel, Małgorzata and Perenc, Adam and Rudnicka-Czerwiec, Julia and Malska, Ilona and Bartosik-Psujek, Halina},
  title = {Testosterone in Relapsing–Remitting Multiple Sclerosis: A Case–Control Study},
  journal = {Journal of Clinical Medicine},
  year = {2026},
  volume = {15},
  number = {12},
  pages = {4401},
  doi = {10.3390/jcm15124401}
}
Kostenlos starten →